42246 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Sep 23
13:14 UTC
|
ACN
Accenture
|
◎ Target | Keith Bachman ★★★★☆ #919 | Market Perform | $150.00→ $200.00+33.3% |
|
Sep 23
13:14 UTC
|
TTE
TotalEnergies
|
↓ Downgrade | firm only | Overweight→ Neutral | |
|
Sep 23
13:14 UTC
|
O
Realty Income
|
↓ Downgrade | Nicholas Yulico ★★★☆☆ #1569 | Sec→ r Outperform ➝ Sector Perform | $59.00 |
|
Sep 23
13:14 UTC
|
DCH
American Axle & Manufacturing
|
↓ Downgrade | firm only | Buy→ Hold | $7.10 |
|
Sep 23
13:14 UTC
|
CBZ
CBIZ
|
↓ Downgrade | firm only | Outperform→ Market Perform | |
|
Sep 23
13:14 UTC
|
ALV
Autoliv
|
↓ Downgrade | Emmanuel Rosner ★☆☆☆☆ #2906 | Outperform→ Peer Perform | |
|
Sep 23
13:14 UTC
|
RXO
RXO
|
↑ Upgrade | Bascome Majors ★★★★☆ #804 | Negative→ Neutral | $19.00 |
|
Sep 23
13:14 UTC
|
MGY
Magnolia Oil & Gas
|
↑ Upgrade | firm only | Hold→ Buy | $30.00→ $32.00+6.7% |
|
Sep 23
13:14 UTC
|
LKFT
Lakefront Biotherapeutics American Depositary Shares
|
↑ Upgrade | Brian Abrahams ★★☆☆☆ #2524 | Sec→ r Perform ➝ Outperform | $26.00→ $45.00+73.1% |
|
Sep 23
13:14 UTC
|
GPK
Graphic Packaging
|
↑ Upgrade | Detlef Winckelmann ★★☆☆☆ #2292 | Neutral→ Overweight | $12.50→ $11.50-8.0% |
|
Sep 23
13:14 UTC
|
EDIT
Editas Medicine
|
↑ Upgrade | Debjit Chattopadhyay ★★☆☆☆ #2327 | Neutral→ Buy | $5.00 |
|
Sep 23
12:14 UTC
|
WIX
Wix.com
|
◎ Target | Bernie McTernan ★★★☆☆ #1178 | Buy | $80.00→ $95.00+18.8% |
|
Sep 23
12:14 UTC
|
VLO
Valero Energy
|
◎ Target | Neil Mehta ★★★☆☆ #1523 | Buy | $365.00→ $457.00+25.2% |
|
Sep 23
12:14 UTC
|
TLSI
TriSalus Life Sciences
|
◎ Target | Swayampakula Ramakanth ★★☆☆☆ #2567 | Buy | $11.00→ $12.00+9.1% |
|
Sep 23
12:14 UTC
|
RTX
RTX
|
◎ Target | Douglas Harned ★★☆☆☆ #2290 | Market Perform | $232.00→ $223.00-3.9% |
|
Sep 23
12:14 UTC
|
RKH
Rockhopper Exploration
|
◎ Target | firm only | Buy | GBX 130→ GBX 135+3.8% |
|
Sep 23
12:14 UTC
|
RBLX
Roblox
|
◎ Target | Bernie McTernan ★★★☆☆ #1178 | Buy | $50.00→ $55.00+10.0% |
|
Sep 23
12:14 UTC
|
META
Meta Platforms
|
◎ Target | Deepak Mathivanan ★★★★☆ #699 | Overweight | $680.00→ $860.00+26.5% |
|
Sep 23
12:14 UTC
|
META
Meta Platforms
|
◎ Target | Justin Patterson ★★★★☆ #672 | Overweight | $780.00→ $900.00+15.4% |
|
Sep 23
12:14 UTC
|
KMX
CarMax
|
◎ Target | Daniela Haigian ★★☆☆☆ #2413 | Equal Weight | $44.00→ $47.00+6.8% |
|
Sep 23
12:14 UTC
|
KLC
KinderCare Learning Companies
|
◎ Target | Toni Kaplan ★★★☆☆ #1374 | Underweight | $2.50→ $2.00-20.0% |
|
Sep 23
12:14 UTC
|
KBH
KB Home
|
◎ Target | Rafe Jadrosich ★★★☆☆ #1802 | Neutral | $56.00→ $54.00-3.6% |
|
Sep 23
12:14 UTC
|
CLDX
Celldex Therapeutics
|
◎ Target | Judah Frommer ★★☆☆☆ #2358 | Overweight | $50.00→ $57.00+14.0% |
|
Sep 23
12:13 UTC
|
CBZ
CBIZ
|
↓ Downgrade | firm only | Market Perform | |
|
Sep 23
12:13 UTC
|
EDIT
Editas Medicine
|
↑ Upgrade | firm only | Buy | |
|
Sep 23
10:13 UTC
|
STAN
Standard Chartered
|
◎ Target | firm only | Neutral | GBX 2,230→ GBX 2,370+6.3% |
|
Sep 23
10:13 UTC
|
SMIN
Smiths Group
|
◎ Target | firm only | Buy | GBX 3,000→ GBX 3,200+6.7% |
|
Sep 23
10:13 UTC
|
SDLF
Standard Life
|
◎ Target | firm only | Sec→ r perform | GBX 885→ GBX 970+9.6% |
|
Sep 23
10:13 UTC
|
NWG
NatWest Group
|
◎ Target | firm only | Buy | GBX 840→ GBX 860+2.4% |
|
Sep 23
10:13 UTC
|
KGF
Kingfisher
|
◎ Target | firm only | Hold | GBX 295→ GBX 320+8.5% |
|
Sep 23
10:13 UTC
|
HSBA
HSBC
|
◎ Target | firm only | Neutral | GBX 1,570→ GBX 1,640+4.5% |
|
Sep 23
10:13 UTC
|
HAS
Hays
|
◎ Target | firm only | Neutral | GBX 33→ GBX 65+97.0% |
|
Sep 23
10:13 UTC
|
BP
BP
|
◎ Target | firm only | Overweight | GBX 550→ GBX 675+22.7% |
|
Sep 23
10:13 UTC
|
BOKU
Boku
|
◎ Target | firm only | Buy | GBX 200→ GBX 210+5.0% |
|
Sep 23
10:13 UTC
|
BARC
Barclays
|
◎ Target | firm only | Neutral | GBX 510→ GBX 500-2.0% |
|
Sep 23
10:13 UTC
|
ABF
Associated British Foods
|
◎ Target | firm only | Sec→ r perform | GBX 1,550→ GBX 1,520-1.9% |
|
Sep 23
10:13 UTC
|
SMGZY
Smiths Group
|
↓ Downgrade | firm only | Buy→ Neutral | |
|
Sep 23
10:13 UTC
|
ARX
Accelerant
|
↓ Downgrade | C. Gregory Peters not yet tracked | Market Perform→ Underperform | |
|
Sep 23
10:13 UTC
|
RTO
Rentokil Initial
|
↑ Upgrade | firm only | Buy | |
|
Sep 23
10:13 UTC
|
LKFT
Lakefront Biotherapeutics American Depositary Shares
|
↑ Upgrade | firm only | Buy | |
|
Sep 23
10:13 UTC
|
CAIXY
CaixaBank
|
↑ Upgrade | firm only | Buy | |
|
Sep 23
00:12 UTC
|
XMTR
Xometry
|
◎ Target | Scott Devitt ★★★☆☆ #1996 | Buy | $110.00→ $120.00+9.1% |
|
Sep 23
00:12 UTC
|
WBD
Warner Bros. Discovery
|
◎ Target | Sean Diffley ★★☆☆☆ #2346 | Equal Weight | $29.00→ $31.00+6.9% |
|
Sep 23
00:12 UTC
|
WAL
Western Alliance Bancorporation
|
◎ Target | Benjamin Gerlinger not yet tracked | Buy | $98.00→ $95.00-3.1% |
|
Sep 23
00:12 UTC
|
VRDN
Viridian Therapeutics
|
◎ Target | Lisa Walter ★★☆☆☆ #2710 | Outperform | $36.00→ $38.00+5.6% |
|
Sep 23
00:12 UTC
|
TYRA
Tyra Biosciences
|
◎ Target | Mitchell S. Kapoor not yet tracked | Buy | $30.00→ $29.00-3.3% |
|
Sep 23
00:12 UTC
|
TWLO
Twilio
|
◎ Target | Catharine Trebnick ★★★☆☆ #1811 | Buy | $275.00→ $290.00+5.5% |
|
Sep 23
00:12 UTC
|
TWLO
Twilio
|
◎ Target | Derrick Wood ★★★☆☆ #1484 | Buy | $260.00→ $300.00+15.4% |
|
Sep 23
00:12 UTC
|
TPB
Turning Point Brands
|
◎ Target | Ian Zaffino ★★★☆☆ #1035 | Outperform | $130.00→ $90.00-30.8% |
|
Sep 23
00:12 UTC
|
TCBI
Texas Capital Bancshares
|
◎ Target | Benjamin Gerlinger not yet tracked | Neutral | $107.00→ $104.00-2.8% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.